Law360, New York (September 03, 2010, 11:23 AM ET) -- A federal judge has brought an end to multidistrict litigation claiming biotechnology company InterMune Inc. fraudulently promoted its drug Actimmune as a remedy for a deadly lung disease it was not approved to treat.
Judge Marilyn Hall Patel of the U.S. District Court for the Northern District of California on Wednesday dismissed the case with prejudice, ruling that the plaintiffs — a proposed class of patients as well as insurer Government Employees Health Association Inc. — had failed in their third attempt to bring actionable claims...
Judge Shuts Down Actimmune Marketing MDL
To view the full article, take a free trial now.
